Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
Super League Enterprise And 2 Other Stocks Under $2 Insiders Are Buying
超級聯賽企業和其他2只股票在$2以下,內部人士正在購買
The Dow Jones index closed lower by over 500 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and traders interested in penny stocks can consider this a factor in their overall investment or trading decision.
道瓊斯指數週三下跌超過500點。當內部人員購買或出售股票時,這表明他們對公司前景的信心或擔憂。對於有興趣投資或交易低價股票的投資者和交易者來說,可以考慮這一因素作爲他們整體投資或交易決策的一個因素。
Below is a look at a few recent notable insider transactions for penny stocks. For more, check out Benzinga's insider transactions platform.
以下是幾個近期關於低價股的值得關注的內部交易。了解更多,請查看Benzinga內幕交易平台。
Super League Enterprise
Super League Enterprise
- The Trade: Super League Enterprise, Inc. (NASDAQ:SLE) Director Jeff Patrick Gehl bought a total of 50,000 shares at an average price of $1.35. To acquire these shares, it cost around $67,548.
- What's Happening: On June 21, Super League issued a mid-year update from the Company's Chief Executive Office, Ann Hand.
- What Super League Enterprise Does: Super League Enterprise Inc is the rocket ship to the metaverse.
- 交易:Super League Enterprise,Inc.(NASDAQ:SLE)董事Jeff Patrick Gehl在平均價格爲1.35美元的情況下購買了總共50,000股。要獲得這些股份,花費大約67,548美元。
- 正在發生什麼:6月21日,超級聯賽(Super League)發佈了公司首席執行官Ann Hand的半年度更新。
- 超級聯賽企業是通往元宇宙的火箭船。
aTyr Pharma
atyr pharma
- The Trade: aTyr Pharma, Inc. (NASDAQ:ATYR) Director Paul Schimmel acquired a total of 100,000 shares at an average price of $1.85. To acquire these shares, it cost around $184,613.
- What's Happening: On July 22, HC Wainwright & Co. analyst Joseph Pantginis reiterated aTyr Pharma with a Buy rating and maintained a $35 price target.
- What aTyr Pharma Does: aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform.
- 交易:aTyr Pharma,Inc.(NASDAQ:ATYR)董事Paul Schimmel以平均價格1.85美元的價格購買了總共100,000股。購買這些股票的成本約爲184,613美元。
- 動態:7月22日,HC Wainwright&Co.分析師Joseph Pantginis重申對atyr pharma的買入評級,並維持35美元的目標價格。
- atyr pharma的業務是從其專有的tRNA合成酶平台發現和開發首創藥物的生物治療公司。
Retractable Technologies
Retractable Technologies
- The Trade: Retractable Technologies, Inc. (NYSE:RVP) President and CEO Thomas J Shaw acquired a total of 8,788 shares at an average price of $1.09. The insider spent around $9,579 to buy those shares.
- What's Happening: On May 15, Retractable Technologies posted a decline in quarterly sales results.
- What Retractable Technologies Does: Retractable Technologies Inc designs, develops, manufactures, and markets safety syringes and other safety medical products for the healthcare profession.
- 交易:Retractable Technologies,Inc.(NYSE:RVP)總裁兼首席執行官Thomas J Shaw在平均價格爲1.09美元的情況下購買了總共8,788股。內部人員花費了大約9,579美元購買這些股份。
- 正在發生什麼事:5月15日,Retractable Technologies發佈了季度銷售結果下降的消息。
- Retractable Technologies Inc設計、開發、製造和銷售安全注射器和其他醫療保健產品,爲醫療保健行業提供安全解決方案。
- Nasdaq, S&P 500 Record Worst Session Since 2022 Amid Tesla, Alphabet Selloff: Investor Optimism Decreases Further
- 納斯達克、標普500指數因特斯拉、Alphabet拋售而創下2022年以來最劣表現:投資者信心進一步降低。